RESUMO
BACKGROUND: Lung ultrasound has demonstrated its usefulness in several respiratory diseases management. One derived score, the Lung Ultrasound (LUS) score, is considered a good outcome predictor in patients with Acute Respiratory Failure (ARF). Nevertheless, it has not been tested in patients undergoing non-invasive respiratory support (NIRS). Taking this into account, the aim of this study is to evaluate LUS score as a predictor of 90-day mortality, ETI (Endotracheal intubation) and HFNC (High Flow Nasal Cannula) failure in patients with ARF due to COVID-19 admitted to a Respiratory Intermediate Care Unit (RICU) for NIRS management. RESULTS: One hundred one patients were admitted to the RICU during the study period. Among these 76% were males and the median age was 55 (45-64) years. Initial ARF management started with HFNC, the next step was the use of Continuous Positive Airway Pressure (CPAP) devices and the last intervention was ETI and Intensive Care Unit (ICU) admission. Of the total study population, CPAP was required in 40%, ETI in 26%, while 15% died. By means of a ROC analysis, a LUS ≥ 25 points was identified as the cut-off point for mortality(AUC 0.81, OR 1.40, 95% CI 1.14 to 1.71; p < 0.001), ETI (AUC 0.83, OR 1.43, 95% CI 1.20 to 1.70; p < 0.001) and HFNC failure (AUC 0.75, OR 1.25, 95% CI 1.12 to 1.41; p < 0.001). Kaplan-Meier survival curves also identified LUS ≥ 25 as a predictor of 90-days mortality (HR 4.16, 95% CI 1.27-13.6) and 30 days ETI as well. CONCLUSION: In our study, a ≥ 25 point cut-off of the Lung Ultrasound Score was identified as a good outcome prediction factor for 90-days mortality, ETI and HFNC failure in a COVID-19 ARF patients cohort treated in a RICU. Considering that LUS score is easy to calculate, a multicenter study to confirm our findings should be performed.
RESUMO
OBJECTIVE: To evaluate the performance of lung ultrasound to determine short-term outcomes of patients with COVID-19 admitted to the intensive care unit. METHODS: This is a Prospective, observational study. Between July and November 2020, 59 patients were included and underwent at least two LUS assessments using LUS score (range 0-42) on day of admission, day 5th, and 10th of admission. RESULTS: Age was 66.5±15 years, APACHE II was 8.3±3.9, 12 (20%) patients had malignancy, 46 (78%) patients had a non-invasive ventilation/high-flow nasal cannula and 38 (64%) patients required mechanical ventilation. The median stay in ICU was 12 days (IQR 8.5-20.5 days). ICU or hospital mortality was 54%. On admission, the LUS score was 20.8±6.1; on day 5th and day 10th of admission, scores were 27.6±5.5 and 29.4±5.3, respectively (P=0.007). As clinical condition deteriorated the LUS score increased, with a positive correlation of 0.52, P <0.001. Patients with worse LUS on day 5th versus better score had a mortality of 76% versus 33% (OR 6.29, 95%CI 2.01-19.65, p. 0.003); a similar difference was observed on day 10. LUS score of 5th day of admission had an area under the curve of 0.80, best cut-point of 27, sensitivity and specificity of 0.75 and 0.78 respectively. CONCLUSION: These findings position LUS as a simple and reproducible method to predict the course of COVID-19 patients.
Assuntos
COVID-19 , Idoso , Idoso de 80 Anos ou mais , Humanos , Unidades de Terapia Intensiva , Pulmão/diagnóstico por imagem , Pessoa de Meia-Idade , Estudos Prospectivos , SARS-CoV-2 , UltrassonografiaRESUMO
ABSTRACT Objective To evaluate the performance of lung ultrasound to determine short-term outcomes of patients with COVID-19 admitted to the intensive care unit. Methods This is a Prospective, observational study. Between July and November 2020, 59 patients were included and underwent at least two LUS assessments using LUS score (range 0-42) on day of admission, day 5th, and 10th of admission. Results Age was 66.5±15 years, APACHE II was 8.3±3.9, 12 (20%) patients had malignancy, 46 (78%) patients had a non-invasive ventilation/high-flow nasal cannula and 38 (64%) patients required mechanical ventilation. The median stay in ICU was 12 days (IQR 8.5-20.5 days). ICU or hospital mortality was 54%. On admission, the LUS score was 20.8±6.1; on day 5th and day 10th of admission, scores were 27.6±5.5 and 29.4±5.3, respectively (P=0.007). As clinical condition deteriorated the LUS score increased, with a positive correlation of 0.52, P <0.001. Patients with worse LUS on day 5th versus better score had a mortality of 76% versus 33% (OR 6.29, 95%CI 2.01-19.65, p. 0.003); a similar difference was observed on day 10. LUS score of 5th day of admission had an area under the curve of 0.80, best cut-point of 27, sensitivity and specificity of 0.75 and 0.78 respectively. Conclusion These findings position LUS as a simple and reproducible method to predict the course of COVID-19 patients.
RESUMO Objetivo Avaliar o desempenho da ultrassonografia pulmonar para determinar a evolução em curto prazo de pacientes com COVID-19 internados na unidade de terapia intensiva. Métodos Este é um estudo prospectivo e observacional. Entre julho e novembro de 2020, 59 pacientes foram incluídos e submetidos a pelo menos duas avaliações LUS usando o escore LUS (variação de 0-42) no dia da admissão, dia 5 e 10 de admissão. Resultados A idade foi de 66,5 ± 15 anos, APACHE II foi de 8,3 ± 3,9, 12 (20%) pacientes tinham malignidade, 46 (78%) pacientes tinham ventilação não invasiva / cânula nasal de alto fluxo e 38 (64%) pacientes ventilação mecânica necessária. A mediana de permanência na UTI foi de 12 dias (IQR 8,5-20,5 dias). A mortalidade na UTI ou hospitalar foi de 54%. Na admissão, o escore LUS era de 20,8 ± 6,1; no dia 5 e no dia 10 de admissão, os escores foram 27,6 ± 5,5 e 29,4 ± 5,3, respectivamente (P = 0,007). Com a deterioração do quadro clínico, o escore LUS aumentou, com correlação positiva de 0,52, P <0,001. Pacientes com pior LUS no dia 5 versus melhor pontuação tiveram mortalidade de 76% versus 33% (OR 6,29, IC 95% 2,01-19,65, p. 0,003); uma diferença semelhante foi observada no dia 10. O escore LUS do 5º dia de admissão teve uma área sob a curva de 0,80, melhor ponto de corte de 27, sensibilidade e especificidade de 0,75 e 0,78, respectivamente. Conclusão Esses achados posicionam o LUS como um método simples e reprodutível para predizer a evolução de pacientes com COVID-19.